<DOC>
	<DOCNO>NCT00097071</DOCNO>
	<brief_summary>This trial conduct United States America ( USA ) . It demonstrate intensive insulin therapy result good glycaemic control reduce delay incidence complication secondary Type 1 Diabetes . Insulin Aspart ( NovoLog® ) ideal insulin use intensive insulin regimen use continuous subcutaneous insulin injection ( CSII ) therapy pediatric adolescent age population . This trial compare safety efficacy Insulin Aspart ( NovoLog® ) Insulin Lispro ( Humalog® ) deliver CSII child adolescent type 1 diabetes .</brief_summary>
	<brief_title>Safety Efficacy NovoLog vs. Humalog Insulin Pumps Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Type 1 Diabetes</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Diabetes , Type 1</keyword>
</DOC>